Search research articles
Contact Us
Filters
Showing results (171-180 of 246) with videos related to
Page
of 25
Sort By:
European Urology Oncology
|
July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial
Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
The Lancet. Oncology
|
October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
Chad Tang, Pavlos Msaouel, Kieko Hara, et al.
The Oncologist
|
January 14, 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, et al.
JAMA Oncology
|
June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis
Alexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
BMJ Oncology
|
January 31, 2025
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials
Alexander D Sherry, Pavlos Msaouel, Timothy A Lin, et al.
The Oncologist
|
November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy
Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 1, 2024
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials
Alexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
NPJ Precision Oncology
|
July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trials
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
International Journal of Cancer
|
August 14, 2024
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials
Alexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 27, 2025
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
Page
of 25
Search research articles
Search
Showing results (171-180 of 246) with videos related to
Sort By:
Page
of 25
European Urology Oncology
|
July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial
Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
The Lancet. Oncology
|
October 31, 2021
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
Chad Tang, Pavlos Msaouel, Kieko Hara, et al.
The Oncologist
|
January 14, 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, et al.
JAMA Oncology
|
June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis
Alexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
BMJ Oncology
|
January 31, 2025
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials
Alexander D Sherry, Pavlos Msaouel, Timothy A Lin, et al.
The Oncologist
|
November 30, 2023
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy
Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 1, 2024
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials
Alexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
NPJ Precision Oncology
|
July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trials
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
International Journal of Cancer
|
August 14, 2024
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials
Alexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 27, 2025
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials
Alexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
Page
of 25